TIMING Business Summary

Timing Pharmaceutical Co., Ltd. (6659.TWO) operates a diversified healthcare business model centered on the manufacturing and distribution of Traditional Chinese Medicine (TCM), over-the-counter (OTC) drugs, and specialized herbal supplements. The company generates revenue through direct product sales across four primary segments: Traditional Chinese Medicine, Regenerative Medicine (Cell Therapy CDMO), Digital Health, and Diagnostics & Laboratory services. Its product portfolio includes proprietary formulations like the "Timing Herbs" series and NRICM101, alongside a robust Contract Development and Manufacturing Organization (CDMO) arm that provides cell therapy services involving Natural Killer (NK) cells and Mesenchymal Stem Cells (MSCs). Within the competitive landscape of Taiwan’s pharmaceutical sector, Timing contends with established players such as Sun Ten Pharmaceutical, Chuang Song Zong Pharmaceutical, Sinphar Pharmaceutical, and Bora Pharmaceuticals. It distinguishes itself by leveraging its 50-year heritage in herbal medicine to pivot into high-growth biotech niches, effectively bridging traditional therapeutic practices with modern regenerative medicine and TAF-certified laboratory testing. Founded in 1968, the company is currently led by Chairman and General Manager Wang Po-Lun, who maintains a centralized leadership role overseeing both strategic direction and daily operations. The executive team includes Finance Manager and Spokesman Chang Wen-Chang, who manages the firm's fiscal health and public disclosures on the Taipei Exchange (TPEx). Under Wang’s leadership, Timing has evolved from a traditional herbal manufacturer into a multifaceted biotech enterprise, securing a foothold in the emerging cell therapy market through its Good Tissue Practice (GTP) labs and strategic partnerships in clinical-grade cell augmentation. The company’s board and investor base reflect its status as a publicly traded entity in Taiwan, focused on scaling its CDMO capabilities and expanding its digital health consultation services to address the aging population's demand for integrated chronic disease management.